Volume 58, Issue 3, Pages (September 2000)

Slides:



Advertisements
Similar presentations
Volume 72, Issue 7, Pages (October 2007)
Advertisements

Volume 66, Issue 1, Pages (July 2004)
Volume 60, Issue 3, Pages (September 2001)
Volume 62, Issue 4, Pages (October 2002)
Volume 58, Issue 1, Pages (July 2000)
Volume 72, Issue 10, Pages (November 2007)
Volume 68, Issue 6, Pages (December 2005)
Syntaxin 3 and Munc-18-2 in epithelial cells during kidney development
Volume 66, Issue 3, Pages (September 2004)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Volume 54, Issue 3, Pages (September 1998)
Expression of the C-C chemokine receptor 5 in human kidney diseases1
Volume 82, Issue 8, Pages (October 2012)
Volume 72, Issue 6, Pages (September 2007)
Volume 61, Issue 5, Pages (May 2002)
Volume 53, Issue 4, Pages (April 1998)
Volume 75, Issue 10, Pages (May 2009)
Genistein protects the kidney from cisplatin-induced injury
Volume 62, Issue 1, Pages (July 2002)
Volume 63, Issue 4, Pages (April 2003)
Volume 63, Issue 1, Pages (January 2003)
CD44-mediated neutrophil apoptosis in the rat
Volume 62, Issue 3, Pages (September 2002)
Paricalcitol attenuates cyclosporine-induced kidney injury in rats
Volume 60, Issue 1, Pages (July 2001)
Volume 82, Issue 9, Pages (November 2012)
Volume 70, Issue 12, Pages (December 2006)
Volume 63, Issue 2, Pages (February 2003)
Michel Le Hir, Valérie Besse-Eschmann  Kidney International 
Volume 54, Issue 6, Pages (January 1998)
Volume 56, Issue 3, Pages (September 1999)
A new mouse model of immune-mediated podocyte injury
Volume 81, Issue 9, Pages (May 2012)
Yang Wang, Yi Ping Wang, Yuet-Ching Tay, David C.H. Harris 
Volume 54, Issue 5, Pages (November 1998)
Volume 58, Issue 3, Pages (September 2000)
Volume 63, Issue 5, Pages (May 2003)
Gilbert R. Kinsey, Liping Huang, Amy L. Vergis, Li Li, Mark D. Okusa 
Hepatocyte growth factor suppresses interstitial fibrosis in a mouse model of obstructive nephropathy  Shinya Mizuno, Kunio Matsumoto, Toshikazu Nakamura 
Volume 60, Issue 3, Pages (September 2001)
Volume 60, Issue 1, Pages (July 2001)
Volume 70, Issue 7, Pages (October 2006)
Volume 64, Issue 4, Pages (October 2003)
Volume 62, Issue 2, Pages (August 2002)
Volume 61, Issue 6, Pages (June 2002)
Volume 54, Issue 2, Pages (August 1998)
Volume 57, Issue 3, Pages (March 2000)
Volume 70, Issue 2, Pages (July 2006)
Volume 73, Issue 12, Pages (June 2008)
Regulatory interactions of αβ and γλ T cells in glomerulonephritis
Akira Shimizu, Kazuhiko Yamada, David H. Sachs, Robert B. Colvin 
Volume 56, Issue 2, Pages (August 1999)
Volume 56, Issue 3, Pages (September 1999)
Volume 63, Issue 5, Pages (May 2003)
Volume 59, Issue 3, Pages (March 2001)
The L1 cell adhesion molecule is a potential biomarker of human distal nephron injury in acute tubular necrosis  Y. Allory, V. Audard, P. Fontanges, P.
Volume 66, Issue 1, Pages (July 2004)
Volume 75, Issue 5, Pages (March 2009)
Volume 79, Issue 2, Pages (January 2011)
Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis  H.-C. Yang, L.-J. Ma, J. Ma, A.B. Fogo 
Volume 72, Issue 7, Pages (October 2007)
Volume 57, Issue 1, Pages (January 2000)
T cells as mediators in renal ischemia/reperfusion injury
Volume 58, Issue 1, Pages (July 2000)
Increased survival and reduced renal injury in MRL/lpr mice treated with a novel sphingosine-1-phosphate receptor agonist  Scott E. Wenderfer, Stanislaw.
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
Volume 58, Issue 5, Pages (November 2000)
Volume 63, Issue 1, Pages (January 2003)
Volume 60, Issue 3, Pages (September 2001)
Volume 87, Issue 6, Pages (June 2015)
Presentation transcript:

Volume 58, Issue 3, Pages 1121-1134 (September 2000) Antibodies to both ICAM-1 and LFA-1 do not protect the kidney against toxic (HgCl2) injury  Manuela Ghielli, Walter A. Verstrepen, Kathleen E.J. De Greef, Mark H. Helbert, Dirk K. Ysebaert, Etienne J. Nouwen, Marc E. De Broe  Kidney International  Volume 58, Issue 3, Pages 1121-1134 (September 2000) DOI: 10.1046/j.1523-1755.2000.00269.x Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 In vivo saturation of rat peripheral blood leukocytes (PBLs) by antileukocyte function associated antigen-1 (anti-LFA-1; WT.1) binding. (A) Flow cytometric analysis of rat PBL labeled with anti–LFA-1 [monoclonal antibody (mAb) WT.1] prior to antibody treatment (day -1) displays three subsets of cells differentially (monocytes > granulocytes > lymphocytes) expressing the antigen. (B) Following injection with control antibody (day 0), no PBL could be found with mouse mAb on their membranes that would be recognized by rabbit-anti-mouse (RAM) IgG. (C) In vitro addition of mAb WT.1 displays three subsets of cells differentially expressing the antigen (as in A). (D) Twenty-four hours following combined in vivo treatment with anti–ICAM-1/anti–LFA-1 (day 0), three subsets of cells differentially (consistent with pattern shown in A) binding a mouse antibody are recognized by RAM-IgG. (E) In contrast, hardly any in vitro added mAb WT.1 bound to the cells. White overlays represent nonlabeled autofluorescent controls. Abbreviations are: RAM-IgG, biotinylated rabbit-anti-mouse immunoglobulins; SA-PE, streptavidin-phycoerythrin conjugate. Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 In vivo binding to rat endothelium of injected anti-intercellular adhesion molecule-1 (ICAM-1; mAb WT.1). Immunohistochemical staining by mere addition of secondary polyclonal (horse-anti-mouse) antibody, that is without primary specific mAb of (A) renal tissue sections originating from rats treated with anti–ICAM-1/anti–LFA-1 mAbs revealed intense staining in the renal interstitium as well as in glomeruli presumably representing ICAM-1–expressing endothelial cells to which injected mouse-anti-rat ICAM-1 (mAb 1A29) is bound. (B) Renal tissue originating from rats treated with control mAb were negative. (C) Immunohistochemical staining with anti–ICAM-1 mAb from renal tissue obtained from rats treated with control mAb four days after mercuric chloride injection shows the ICAM-1 expression to correspond with horse-anti-mouse staining pattern in A (magnification 10 × 1.25 × 25). Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Interstitial infiltration of mononuclear cells. The number of positive cells upon immunohistochemical staining of renal tissue sections with (A–C) mAb ED1 (macrophages), (D–F) mAb OX-8 (CD8-positive cells), and (G–I) mAb OX-35 (CD4-positive cells). Whereas control antibody (B, E, and H) and vehicle (C, F, and I)-treated rats showed marked interstitial numbers of these three leukocyte subsets, infiltration was suppressed in anti–ICAM-1/anti–LFA-1 (A, D, and G) treated rats. Nevertheless, macrophages were apparent at day 6 in the anti-adhesion treated group. *P < 0.05 as compared with non–HgCl2-injected control within one treatment group. #P < 0.05 between anti-adhesion and control mAb-treated groups. °P < 0.05 between anti-adhesion and vehicle-treated groups. Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Macrophages in the rat kidney after HgCl2 injection. Immunohistochemical staining of renal tissue sections obtained at day 4 from (A) control antibody-treated rats and (B) anti–ICAM-1/anti–LFA-1 treated rats. Microwave treatment + mAb ED1 (magnification 10 × 1.25 × 25). Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Alterations in renal function. (A–C) Serum creatinine concentration and (D–F) urinary protein excretion increased after mercuric chloride injection to a maximum at day 2, after which both these parameters for renal function recovered. The alterations were equivalent in all treatment groups. (Paired t-test between data from days -1, 1, 2, 4, 6, 8, and 10, and day 0.) Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Proximal tubular epithelial cell injury in the outer stripe of the outer medulla. Within 24 hours after mercuric chloride injection, pronounced proximal (S3 segment) tubular necrosis had evolved, which increased somewhat by day 2. Thereafter, necrotic cells were gradually replaced by healthy cells, and this at a comparable rate in all groups. Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 7 Proliferating cell nuclear antigen (PCNA) expression as an indicator of cell proliferation. PCNA positivity was highest in proximal tubules (A–C), although some distal tubular (D–F) as well as interstitial (G–I) cell proliferation also was apparent. Peak proliferation in proximal tubules (day 4) was higher in control antibody (B) and vehicle (C)-treated rats as compared with anti–ICAM-1/anti–LFA-1 (A)-treated rats. Also, distal tubular proliferation started sooner (day 2) in control antibody (E) and vehicle (F) treated rats as compared with anti-adhesion treated rats (D). *P < 0.05 as compared with non-HgCl2 injected control within one treatment group. Kidney International 2000 58, 1121-1134DOI: (10.1046/j.1523-1755.2000.00269.x) Copyright © 2000 International Society of Nephrology Terms and Conditions